These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 24293576)

  • 1. Effect of biologic treatments on growth in children with juvenile idiopathic arthritis.
    Uettwiller F; Perlbarg J; Pinto G; Bader-Meunier B; Mouy R; Compeyrot-Lacassagne S; Melki I; Wouters C; Prieur AM; Landais P; Polak M; Quartier P
    J Rheumatol; 2014 Jan; 41(1):128-35. PubMed ID: 24293576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
    Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
    Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt.
    Mourão AF; Santos MJ; Melo Gomes JA; Martins FM; Mendonça SC; Oliveira Ramos F; Fernandes S; Salgado M; Guedes M; Carvalho S; Costa JA; Brito I; Duarte C; Furtado C; Lopes A; Rodrigues A; Sequeira G; Branco JC; Fonseca JE; Canhão H
    Rheumatology (Oxford); 2016 Apr; 55(4):697-703. PubMed ID: 26672905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease activity of idiopathic juvenile arthritis continues through adolescence despite the use of biologic therapies.
    Vidqvist KL; Malin M; Varjolahti-Lehtinen T; Korpela MM
    Rheumatology (Oxford); 2013 Nov; 52(11):1999-2003. PubMed ID: 23893666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth and body mass index in a cohort of patients with juvenile idiopathic arthritis: effects of second line treatments.
    Marino A; Stagi S; Simonini G; Carli N; Caparello MC; Giani T; Pagnini I; De Masi S; Cimaz R
    Clin Exp Rheumatol; 2018; 36(5):929-933. PubMed ID: 30148444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
    Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel treatment options for juvenile idiopathic arthritis.
    Steigerwald KA; Ilowite NT
    Expert Rev Clin Pharmacol; 2015; 8(5):559-73. PubMed ID: 26294075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Guidelines on biologic drugs for the treatment of children with juvenile idiopathic arthritis (JIA)].
    Bukovac LT; Vidović M; Lamot L; Perica M; Harjacek M;
    Reumatizam; 2013; 60(1):57-66. PubMed ID: 24003687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in body mass index in children with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors.
    Shafferman A; Fontaine KR; Cron RQ; Beukelman T
    J Rheumatol; 2014 Jan; 41(1):113-8. PubMed ID: 24293573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth in children and adolescents with juvenile idiopathic arthritis over 2 years of treatment with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.
    Kearsley-Fleet L; Hyrich KL; Davies R; Lunt M; Southwood TR;
    Rheumatology (Oxford); 2015 Jul; 54(7):1279-85. PubMed ID: 25638806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS).
    Davies R; Carrasco R; Foster HE; Baildam EM; Chieng SEA; Davidson JE; Ioannou Y; Wedderburn LR; Thomson W; Hyrich KL
    Semin Arthritis Rheum; 2016 Oct; 46(2):190-195. PubMed ID: 27422803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort.
    Guzman J; Oen K; Tucker LB; Huber AM; Shiff N; Boire G; Scuccimarri R; Berard R; Tse SM; Morishita K; Stringer E; Johnson N; Levy DM; Duffy KW; Cabral DA; Rosenberg AM; Larché M; Dancey P; Petty RE; Laxer RM; Silverman E; Miettunen P; Chetaille AL; Haddad E; Houghton K; Spiegel L; Turvey SE; Schmeling H; Lang B; Ellsworth J; Ramsey S; Bruns A; Campillo S; Benseler S; Chédeville G; Schneider R; Yeung R; Duffy CM;
    Ann Rheum Dis; 2015 Oct; 74(10):1854-60. PubMed ID: 24842571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etanercept treatment improves longitudinal growth in prepubertal children with juvenile idiopathic arthritis.
    Vojvodich PF; Hansen JB; Andersson U; Sävendahl L; Hagelberg S
    J Rheumatol; 2007 Dec; 34(12):2481-5. PubMed ID: 18050366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis.
    Nordal E; Zak M; Aalto K; Berntson L; Fasth A; Herlin T; Lahdenne P; Nielsen S; Straume B; Rygg M;
    Arthritis Rheum; 2011 Sep; 63(9):2809-18. PubMed ID: 21560116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parents' willingness to pay for biologic treatments in juvenile idiopathic arthritis.
    Burnett HF; Ungar WJ; Regier DA; Feldman BM; Miller FA
    Value Health; 2014 Dec; 17(8):830-7. PubMed ID: 25498778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth During Tocilizumab Therapy for Polyarticular-course Juvenile Idiopathic Arthritis: 2-year Data from a Phase III Clinical Trial.
    Bharucha KN; Brunner HI; Calvo Penadés I; Nikishina I; Rubio-Pérez N; Oliveira S; Kobusinska K; Schmeling H; Sztajnbok F; Weller-Heinemann F; Zholobova E; Zulian F; Allen R; Chaitow J; Frane J; Wells C; Ruperto N; De Benedetti F;
    J Rheumatol; 2018 Aug; 45(8):1173-1179. PubMed ID: 29961686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement in health-related quality of life for children with juvenile idiopathic arthritis after start of treatment with etanercept.
    Klotsche J; Minden K; Thon A; Ganser G; Urban A; Horneff G
    Arthritis Care Res (Hoboken); 2014 Feb; 66(2):253-62. PubMed ID: 23983081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian reserve in children with juvenile idiopathic arthritis using biologic disease-modifying anti-rheumatic drugs.
    Ozer Y; Yildiz M; Turan H; Tarcin G; Bingol Aydin D; Gunalp A; Haslak F; Kilic Konte E; Aslan E; Koker O; Bayramoglu E; Sahin S; Adrovic A; Barut K; Kasapcopur O; Evliyaoglu O
    Clin Rheumatol; 2024 Jan; 43(1):399-406. PubMed ID: 37646858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Physical development in children with juvenile idiopathic arthritis].
    Umławska W; Michałowska J; Podwysocka-Harasimowicz M
    Pediatr Endocrinol Diabetes Metab; 2008; 14(3):161-4. PubMed ID: 18922221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome and Trends in Treatment of Systemic Juvenile Idiopathic Arthritis in the German National Pediatric Rheumatologic Database, 2000-2013.
    Klotsche J; Raab A; Niewerth M; Sengler C; Ganser G; Kallinich T; Niehues T; Hufnagel M; Thon A; Hospach T; Horneff G; Minden K
    Arthritis Rheumatol; 2016 Dec; 68(12):3023-3034. PubMed ID: 27332999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.